Gilead Sciences - GILD Stock Forecast, Price & News

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View GILD analyst ratings or view top-rated stocks.

17 analysts have issued 12 month price targets for Gilead Sciences' stock. Their GILD share price forecasts range from $70.00 to $112.00. On average, they predict the company's stock price to reach $88.55 in the next year. This suggests a possible upside of 2.9% from the stock's current price.
View analysts price targets for GILD or view top-rated stocks among Wall Street analysts.

Gilead Sciences' stock was trading at $85.85 at the start of the year. Since then, GILD shares have increased by 0.2% and is now trading at $86.05.
View the best growth stocks for 2023 here.

Gilead Sciences saw a drop in short interest in January. As of January 15th, there was short interest totaling 14,930,000 shares, a drop of 8.0% from the December 31st total of 16,220,000 shares. Based on an average daily trading volume, of 7,960,000 shares, the days-to-cover ratio is currently 1.9 days.
View Gilead Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our GILD earnings forecast.

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings data on Thursday, February, 2nd. The biopharmaceutical company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.50 by $0.17. The biopharmaceutical company earned $7.39 billion during the quarter, compared to the consensus estimate of $6.63 billion. Gilead Sciences had a trailing twelve-month return on equity of 44.46% and a net margin of 16.83%. The business's quarterly revenue was up 2.0% compared to the same quarter last year. During the same period last year, the firm posted $0.69 EPS.
Read the conference call transcript.

Gilead Sciences announced a quarterly dividend on Thursday, February 2nd. Shareholders of record on Wednesday, March 15th will be given a dividend of $0.75 per share on Thursday, March 30th. This represents a $3.00 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend is Tuesday, March 14th. This is a boost from the stock's previous quarterly dividend of $0.73.
Read our dividend analysis for GILD.

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 3.38%. The company has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 80.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, GILD will have a dividend payout ratio of 39.84% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

Gilead Sciences updated its FY 2023 earnings guidance on Thursday, February, 2nd. The company provided earnings per share (EPS) guidance of $6.60-$7.00 for the period, compared to the consensus earnings per share estimate of $6.73. The company issued revenue guidance of $26.00 billion-$26.50 billion, compared to the consensus revenue estimate of $25.76 billion.

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Parnassus Investments LLC (0.96%), Sumitomo Mitsui Trust Holdings Inc. (0.34%), Robeco Institutional Asset Management B.V. (0.29%), Envestnet Asset Management Inc. (0.22%), Pacer Advisors Inc. (0.21%) and Railway Pension Investments Ltd (0.19%). Insiders that own company stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey and Richard James Whitley.
View institutional ownership trends.

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GILD stock can currently be purchased for approximately $86.05.

Gilead Sciences (NASDAQ:GILD) has a market capitalization of $107.93 billion and generates $27.28 billion in revenue each year. The biopharmaceutical company earns $4.59 billion in net income (profit) each year or $3.65 on an earnings per share basis.

The company employs 14,400 workers across the globe.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.gilead.com. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at investor_relations@gilead.com, or via fax at 650-578-9264.